drugset / Trial / NCT05559541
Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This is a Phase Ib/II Study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK119 combined with AK104 in tumor patients.
Timeline
- Start
- 2022-12-15
- Primary completion
- 2024-05-31
- Completion
- 2024-05-31
Outcome
Outcome not reported
Stopped (Business): “Development strategy adjustment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK119 | Monoclonal antibody | — | Intravenous |
| Subject | Cadonilimab | Monoclonal antibody | — | Intravenous |